The Cell Surface Markers Detection market includes various products involved in the treatment of various types of blood cancers such as leukemia, lymphoma and multiple myeloma. These products include chemotherapy drugs, immunotherapy drugs, supportive care drugs and stem cell transplant. The selection of drug depends on type and stage of cancer. For example, chemotherapy remains first line therapy for many types of leukemias while targeted therapies and immunotherapies are used for relapsed or refractory cases.

The global Cell Surface Markers Detection market is estimated to be valued at US$ 5,459.5 Mn in 2023 and is expected to exhibit a CAGR of 9.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:
One of the major drivers propelling the growth of Cell Surface Markers Detection market is rising geriatric population globally. Aging is one of the strongest risk factors for developing blood cancers. For instance, according to WHO, number of people aged 65 years and above is projected to grow from 703 million in 2019 to 1.5 billion in 2050 globally. Elderly people are more likely to develop hematological malignancies owing to compromised immune system with age. This substantial rise in aging population base will correspondingly fuel the incidence of hematological cancers thereby driving the market growth of associated therapeutics over the forecast period. Additionally, increasing adoption of targeted therapies and continuous pipeline of novel therapeutics in clinical development will also contribute to market growth. However, expensive cost of newly approved therapies continues to remain a challenge.

SWOT Analysis

Strength: Cell surface markers detection technologies offer highly specific and sensitive analysis of cells. Several markers can be detected simultaneously using flow cytometry or other multi-parameter techniques. This allows complex phenotyping of cells and their classification. Advanced cell surface marker detection kits are user-friendly and deliver accurate results with minimal sample requirements.

Weakness: Cell surface marker detection requires specialized equipment and trained personnel for operation and data analysis. Flow cytometers and other detection instruments are expensive to purchase and maintain. Cell surface markers expression can change depending on cell activation status posing challenges in result interpretation.

Opportunity: Rising funding for cancer and immunology research is driving demand for cell surface markers analysis to better understand disease mechanisms. Growing stem cell therapy research also relies on accurate characterization of cell markers. Development of compact and affordable detection devices expand viable markets in academic research and diagnostic laboratories.

Threats: Stringent regulatory approval pathways for new detection systems delay their commercial adoption. Alternative sample profiling methods may emerge reducing reliance on cell surface markers alone. Economic pressures can restrain capital equipment investments by research organizations.

Key Takeaways

The global cell surface markers detection market is expected to witness high growth over the forecast period supported by ongoing research in oncology, immunology, and regenerative medicine. The global cell surface markers detection market is estimated to be valued at US$ 5,459.5 Mn in 2023 and is expected to exhibit a CAGR of 9.1% over the forecast period 2023 to 2030.
Regional analysis: North America currently dominates the market due to presence of leading life sciences research organizations and advanced healthcare infrastructure. However, Asia Pacific is expected to grow at the fastest pace due growing biomedical industry, increasing healthcare expenditure, and expanding application of cell surface markers techniques in disease diagnostics and therapeutics development.

Key players: Key players operating in the cell surface markers detection market are Grifols SA, Abbott Laboratories, Sysmex Corporation, Agilent Technologies Inc., Nexcelom Bioscience, Thermo Fisher Scientific Inc., Siemens Healthineers, Nihon Kohden Corporation, F. Hoffmann-La Roche Ltd., Bio Rad Laboratories Inc., Becton, Dickinson and Company (BD), Qiagen NV, Diasorin SpA (Luminex Corporation), Danaher Corporation (Beckman Coulter Inc.), and IVD Medical Holding Limited (Immucor Inc.), among others. These companies are focused on developing customized cell marker panels as well as high-throughput analyzer systems for clinical and research use.

Get more insights on this topic:

Cell therapy Manufacturing Market

Platelet RIch Plasma Market

Diabetes Nutrition Market